Studies indicate that ILC1 enhances anti‐tumor responses in murine BC models by interacting with cancer cells and producing IL‐15 and IFNγ, thereby establishing an immune surveillance mechanism against epithelial malignancies [44]; conversely, the infiltration of ILC3 is correlated with BC progression, suggesting that future research may focus on modulating ILC activity to improve immune surveillance and therapeutic outcomes. Here, IFNG is linked to breast cancer.